DR-2313

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameDR-2313
Drug Alias NameDR-2313
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMeiji Seika Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeiji Seika Pharma
Active IndicationsN/A
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksN/A